ArticleAnnals of surgical oncology2026
Utility of 21-Gene Recurrence Score in Male Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecurrence score (RS) is a 21-gene analysis (Oncotype DX) that assesses risk of breast cancer recurrence and benefit from chemotherapy. While extensively validated in female patients, RS has not been well studied in male patients. PATIENTS AND
methodsUsing the National Cancer Database (NCDB) we identified patients with pT1-2, N0-1 estrogen receptor (ER)+ human epidermal growth factor (HER)2- breast cancer (2010-2023) to assess RS usage and prognostic implications. Groups were compared using chi-squared tests. Overall survival (OS) was analyzed using multivariable Cox proportional hazards regression.
resultsWe identified 9908 male and 1,111,898 female patients. While overall rate of RS testing was lower in male (42%) than female (46%) patients, RS use increased markedly between 2010 and 2023 (18-66% in male and 28-62% in female patients), and in 2023, the rate was slightly higher for male patients (p = 0.04). Among those tested, male patients were more likely to have RS ≥ 26 (19% versus 14%, p < 0.001). From 2019 to 2023, chemotherapy use in patients with RS ≥ 26 was lower in male than female patients (68% versus 77%, p < 0.001). Male patients with RS ≥ 26 had significantly poorer OS if chemotherapy was omitted (aHR 1.5, p = 0.03), with a larger difference for male patients aged < 65 years (82% versus 93% 5-year OS without versus with chemotherapy, p = 0.009) than for male patients ≥ 65 years (75% versus 84%, respectively, p = 0.28).
conclusionsRS testing increased between 2010 and 2023 for both sexes, and RS influenced receipt of chemotherapy. Male patients had higher RS but were less likely to receive chemotherapy when RS ≥ 26, and when chemotherapy was omitted, they had worse OS, revealing the importance of chemotherapy among males with high RS.
Indexed as
Identifiers
42113374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.